Skip to search formSkip to main contentSkip to account menu

Goserelin 10.8 MG Drug Implant [Zoladex]

Known as: GOSERELIN ACETATE 10.8 mg SUBCUTANEOUS IMPLANT [ZOLADEX], Zoladex 10.8 MG Drug Implant, Zoladex 10.8 MG Subcutaneous Drug Implant 
National Institutes of Health

Related topics

Related topics

7 relations
DL-Lactic AcidDrug ImplantGoserelinGoserelin Acetate

Broader (1)

Goserelin Drug Implant [Zoladex]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Neues zur Behandlung des metastasierten Prostatakarzinoms
Eine wachsende Anzahl von Medikamenten mit unterschiedlichem Wirkmechanismus hat in den letzten drei Jahren zur Verbesserung des… 
2013
2013
Du nouveau sur le traitement du carcinome prostatique métastatique
Depuis notre aperçu dans Swiss Medical Forum 2010 (2010;10[28–29]:483–5), il y a eu une petite révolution dans le domaine du… 
2002
2002
Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
Correction to: British Journal of Cancer 2001; (Suppl 2): 1–5 An error has been noted within Figure 1. The chemotherapy regimen… 
Review
2001
Review
2001
Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
Current standard adjuvant therapies for premenopausal women with early breast cancer include ovarian ablation by surgery or… 
2001
2001
The ZEBRA study: Reversibility of bone mineral density of pre-/perimenopausal patients with node-positive early breast cancer after treatment with Zoladex™
1997
1997
Associations de radiothérapie et d'hormonothérapie dans les cancers de la prostate localement évolués
1991
1991
Hormonelle Folgetherapien nach Goserelin (Zoladex®) beim metastasierten Mammakarzinom prämenopausaler Patientinnen
Der GnRH-Agonist Zoladex® (Z) (3,6 mg Goserelin; slow releasing depot-Praparat, s.c. alle 4 Wochen appliziert) hat sich als… 
1990
1990
Orchidectomy versus Zoladex® plus Eulexin® in patients with metastatic prostate cancer (EORTC 30853)
1990
1990
Goserelinazetat (Zoladex®) gegen Goserelinazetat plus Flutamid (Fugerel®) beim fortgeschrittenen Prostatakarzinom: Zwischenbericht einer Phase III-Studie
In einer offenen, randomisierten Multizenterstudie (Phase III) wurden die klinische Wirksamkeit und Vertraglichkeit der Goserelin… 
1987
1987
(ZOLADEX®) IN PATIENTS WITH PROSTATIC CARCINOMA
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)